Benjamin Halladay net worth and biography

Benjamin Halladay Biography and Net Worth

Ben has been our Chief Financial Officer since 2022. He was promoted to the CFO role after serving several years in as Esperion’s Senior Director, Financial Planning and Analysis where he oversaw the financial planning and analytics team and partnered with executive leadership and the commercial organization to help the company manage its financial goals. Prior to joining Esperion, Ben held financial and business roles of increasing responsibility with National Oilwell Varco, BMC Software, and Pfizer.

Ben holds a Bachelor of Arts in History from Syracuse University and a Master in Business Administration from Fordham’s Gabelli School of Business.

What is Benjamin Halladay's net worth?: The estimated net worth of Benjamin Halladay is at least $1.80 million as of September 17th, 2025. Halladay owns 474,862 shares of Esperion Therapeutics stock worth more than $1,799,727 as of December 5th. This net worth evaluation does not reflect any other investments that Halladay may own. Learn More about Benjamin Halladay's net worth.
How old is Benjamin Halladay?: Halladay is currently 38 years old. There are 4 older executives and no younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics is Mr. Glenn P. Brame, Chief Technical Operations Officer, who is 66 years old. Learn More on Benjamin Halladay's age.
How do I contact Benjamin Halladay?: The corporate mailing address for Halladay and other Esperion Therapeutics executives is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. Esperion Therapeutics can also be reached via phone at (734) 887-3903 and via email at [email protected]. Learn More on Benjamin Halladay's contact information.
Has Benjamin Halladay been buying or selling shares of Esperion Therapeutics?: Benjamin Halladay has not been actively trading shares of Esperion Therapeutics within the last three months. Most recently, Benjamin Halladay sold 7,046 shares of the business's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $2.81, for a transaction totalling $19,799.26. Following the completion of the sale, the chief financial officer now directly owns 474,862 shares of the company's stock, valued at $1,334,362.22. Learn More on Benjamin Halladay's trading history.
Who are Esperion Therapeutics' active insiders?: Esperion Therapeutics' insider roster includes Benjamin Halladay (CFO), and Benjamin Looker (General Counsel). Learn More on Esperion Therapeutics' active insiders.
Are insiders buying or selling shares of Esperion Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 31,842 shares worth more than $59,811.61. The most recent insider tranaction occured on September, 17th when General Counsel Benjamin Looker sold 6,267 shares worth more than $17,547.60. Insiders at Esperion Therapeutics own 1.7% of the company. Learn More about insider trades at Esperion Therapeutics.
Information on this page was last updated on 9/17/2025.

Benjamin Halladay Insider Trading History at Esperion Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/17/2025	Sell	7,046	$2.81	$19,799.26	474,862
7/17/2025	Sell	11	$1.11	$12.21	474,462
6/17/2025	Sell	7,229	$1.15	$8,313.35	474,473
4/17/2025	Sell	8	$0.96	$7.68	481,702
3/18/2025	Sell	3,535	$1.48	$5,231.80	481,710
2/19/2025	Sell	11	$1.86	$20.46	240,671
1/17/2025	Sell	9	$2.27	$20.43	240,682

Benjamin Halladay Buying and Selling Activity at Esperion Therapeutics

Esperion Therapeutics Company Overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Today's Range

Now: $3.79

$3.76

$3.91

50 Day Range

MA: $2.99

$2.45

$4.00

2 Week Range

Now: $3.79

$0.69

$4.03

Volume

4,725,351 shs

Average Volume

7,200,330 shs

Market Capitalization

$906.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Benjamin Halladay Biography and Net Worth

What is Benjamin Halladay's net worth?

How old is Benjamin Halladay?

How do I contact Benjamin Halladay?

Has Benjamin Halladay been buying or selling shares of Esperion Therapeutics?

Who are Esperion Therapeutics' active insiders?

Are insiders buying or selling shares of Esperion Therapeutics?